Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
Status:
Completed
Trial end date:
2018-11-13
Target enrollment:
Participant gender:
Summary
The study investigates the effect of 3 days of twice daily treatment of two different doses
of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo, each administered in addition
to once daily tiotropium/olodaterol (Respimat) in patients with moderate to severe chronic
obstructive pulmonary disease (COPD). Patients will receive each of the three treatment
combinations in a randomized sequence using a crossover design